Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Inclusion Criteria: * 18-75 years, all genders * Patients with definite B-cell Lymphoma, includes FL, MZL, MCL, DLBCL. * Patients With Relapsed or Refractory B-cell Lymphoma * ECOG ≤ 2 * Lesions are measurable in 21 days before treatment * Normal bone marrow function * Normal liver, kidney, lung and heart function * the Subjects can sign the ICF and obey the protocol, elsewise, his/her guardian should sign * Life expectancy is at least 3 months Exclusion Criteria:• Past or present CNS disease * Associated with lymphoma by the infiltrates of CNS * A history of autoimmune disease with CNS involvement or autoimmune disease * Previous history of autoimmune disease or other malignancy * A history of deep venous thrombosis or pulmonary embolism * Auto-HSCT was performed within 12 weeks prior to initiation of treatment * Previous organ transplantation or allogeneic hematopoietic stem cell transplantation * The Investigator determined that the patients were associated with a disease, medical condition, or social factor that might affect study results or compliance * Immunosuppressant are being used * Radiotherapy was given within 6 weeks prior to A-319 treatment * Chemotherapy, immunotherapy and targeted therapy were received within 4 weeks before A-319 treatment * Previous CAR-T cell therapy * Received anti-lymphoma drugs in the first 4 weeks of A-319 treatment * There was no recovery of toxic effects (CTCAE\> grade 1 adverse events) at the last treatment, except hair loss * Those who underwent major surgery 28 days before enrollment (excluding lymph node biopsy);Or plan to operate during the study period * Those who had received active/attenuated live vaccine within 28 days prior to screening * For pregnant (positive pregnancy test) and lactating women, those of childbearing age who signed the informed consent form and did not agree to use contraception for at least 3 months after the end of the study;Within 7 days prior to the first day of treatment, women of childbearing age require a positive serum pregnancy test (HCG) * Male patients who signed informed consent forms and did not agree to use contraception for at least 3 months at the end of the study (except surgical sterilization) * Known allergy to immunoglobulin or research drugs and their excipients * Patients considered unfit to participate in the study